Trial Profile
Golimumab Intravenous Infusion Registry (GO-IV)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2019
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms GO-IV
- Sponsors Janssen
- 18 Nov 2019 Results published in the Clinical and Experimental Rheumatology
- 08 Nov 2017 Results assessing infusion reactions presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 26 Oct 2016 Status changed from recruiting to discontinued due to business decision based on lack of enrollment.